Cardiovascular Risk in Rheumatoid Arthritis
Cardiovascular risk is an established part of rheumatoid arthritis (RA) care, but recognising a risk is not the same as treating it. Two abstracts at ACR Convergence 2026 highlight this.
Search for Terms or Answers
Cardiovascular risk is an established part of rheumatoid arthritis (RA) care, but recognising a risk is not the same as treating it. Two abstracts at ACR Convergence 2026 highlight this.
Interstitial pneumonia with autoimmune features (IPAF) describes patients who have interstitial lung disease (ILD) plus clinical, serologic, or morphologic features of autoimmunity but who do not meet criteria for a defined connective tissue disease.
Could the therapeutic window of opportunity in rheumatoid arthritis extend beyond preventing structural damage to preventing chronic pain, fatigue, and neuroimmune complications?
Three reports at ACR Convergence 2026 describe CD19 CAR-T cells generated inside the patient, with no apheresis and no ex vivo manufacturing step. None of the three used fludarabine and cyclophosphamide conditioning.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.